Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)

On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy standing for Beam Therapeutics Inc. (NASDAQ:BEAM), pursuing a favorable solution announced by Prime Medicine regarding its arbitration with Beam.

Pressmaster/Shutterstock.com

Stranahan forecasted a people terms of $47, which yields much than 33% upside imaginable astatine the existent level. He highlighted that though the solution went successful Prime's favor, it volition not person overmuch of an interaction connected Beam. This is due to the fact that it is lone applicable to Prime's PM647 alternatively than its full editing estate.

For Beam, Stranahan noted that based connected awesome information for the BEAM-302 biomarker, the absorption present volition beryllium wholly connected the execution of its alpha-1 antitrypsin deficiency. Currently, helium sees Prime arsenic a "distant threat" to the company.

Back connected June 18, Beam Therapeutics Inc. (NASDAQ:BEAM) disclosed that the U.S. FDA has approved the filing of an investigational caller drug, relating to BEAM-304 for phenylketonuria therapy. The institution remains focused connected BEAM-304 utilizing a caller improvement strategy successful which respective mutation-based editors are designed arsenic portion of a unified objective program.

Beam's President, Giuseppe Ciaramella, Ph.D., stated that the FDA support facilitates Beam's attack of designing respective mutation-targeted basal editors via a unified objective level initiative. She besides stated that the institution plans to motorboat its Phase 1/2 trial.

Beam Therapeutics Inc. (NASDAQ:BEAM) is simply a biotechnology institution that develops precision familial medicines and besides engages successful cistron therapies and genome editing research. Since its launch, the institution has been spearheading CRISPR-based editing that facilitates the improvement of precocious familial medicines.

While we admit the imaginable of BEAM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.